Your browser doesn't support javascript.
loading
Rational use of blood products.
Solheim, B G; Wesenberg, F.
Afiliação
  • Solheim BG; Institute of Immunology, Rikshospitalet, The National Hospital University of Oslo, NO-0027 Oslo, Norway. bjarte.solheim@rikshospitalet.no
Eur J Cancer ; 37(18): 2421-5; discussion 2425-7, 2001 Dec.
Article em En | MEDLINE | ID: mdl-11720837
Blood product transfusions can be life saving and must be considered in the supportive care of children of any age with underlying oncological or haematological problems, as well as after major surgery or after serious trauma. Paediatric transfusions are particularly challenging because life-long effects of transfusion complications are more durable and serious in children than in adults, in whom the median age at transfusion is >70 years (Tynell E, Norda R, Shanwell A, Björkman A. Long-term survival in transfusion recipients in Sweden, 1993. Transfusion 2001, 41, 251-255). While the general indications for transfusions in paediatric patients are similar to adults, the threshold, volumes and infusion rates for transfusions vary with age. In this Update, we discuss current blood products, then suggest transfusion "triggers" in major surgery and haematological and oncologic practice. Finally, future developments and new possibilities are considered.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transfusão de Componentes Sanguíneos Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2001 Tipo de documento: Article País de afiliação: Noruega País de publicação: Reino Unido
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transfusão de Componentes Sanguíneos Tipo de estudo: Prognostic_studies Limite: Child / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2001 Tipo de documento: Article País de afiliação: Noruega País de publicação: Reino Unido